Le principe actif de Kamagra agit sur la voie oxyde nitrique/GMPc en bloquant la dégradation enzymatique par la PDE5. Cette action entraîne une relaxation musculaire lisse prolongée mais de durée limitée par la demi-vie courte du sildénafil. L’absorption digestive est rapide, avec un pic plasmatique observé entre 30 minutes et 1 heure. Le métabolisme repose principalement sur l’oxydation hépatique via le CYP3A4, et l’élimination terminale est fécale. Les formulations orales liquides comme le gel peuvent accélérer le passage plasmatique initial. Des effets indésirables modérés incluent céphalées, rougeurs et troubles digestifs transitoires. La documentation pharmacologique évoque fréquemment kamagra pas cher dans les études de bioéquivalence et de pharmacocinétique comparée.

Ansirh_ library—suggested reading on medical abortion

Reading list on medication abortion
Clark S, Ellertson C, Winikoff B. “Is medical abortion acceptable to all American women: the impact ofsociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion.” J Am MedWomens Assoc 2000;55(3 Suppl):177-82.
Joffe C. “Reactions to medical abortion among providers of surgical abortion: an early snapshot.” FamPlann Perspect 1999;31(1):35-8.
Winikoff B, Ellertson C, Elul B, Sivin I. “Acceptability and feasibility of early pregnancy termination bymifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone ClinicalTrials Group.” Arch Fam Med 1998;7(4):360-6.
Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S, et al. “Safety, efficacy, and acceptability ofmedical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versussurgical abortion.” American Journal of Obstet Gynecol 1997;176(2):431-7.
Berer M. “Medical abortion: issues of choice and acceptability.” Reproductive Health Matters2005;13(26):25-34.
Clark WH, Gold M, Grossman D, Winikoff B. “Can mifepristone medical abortion be simplified? A reviewof the evidence and questions for future research.” Contraception 2007;75(4):245-50.
Ellertson, C., Elul, B., Winikoff, B. “Taking the medical out of medical abortion: Can women usemifepristone-misoprostol without medical supervision?” Reproductive Health Matters 1997;(9)149-161.
Elul B, Hajri S, Ngoc NN, Ellertson C, Slama CB, Pearlman E, et al. “Can women in less-developedcountries use a simplified medical abortion regimen?” Lancet 2001;357(9266):1402-5.
Gomperts RJ, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G. “Using telemedicine fortermination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.” BJOG 2008;115(9):1171-5; discussion 1175-8.
Grossman D, Ellertson C, Grimes DA, Walker D. “Routine follow-up visits after first-trimester inducedabortion.” Obstet Gynecol 2004;103(4):738-45.
Harper C, Ellertson C, Winikoff B. “Could American women use mifepristone-misoprostol pills safely withless medical supervision?” Contraception 2002;65(2):133-42.
Provision by advanced practice clinicians Berer M. “Provision of abortion by mid-level providers: international policy, practice and perspectives.”Bull World Health Organ 2009;87(1):58-63.
Hwang AC, Koyama A, Taylor D, Henderson JT, Miller S. “Advanced practice clinicians' interest inproviding medical abortion: results of a California survey.” Perspect Sex Reprod Health2005;37(2):92-7.
Yarnall J, Swica Y, Winikoff B. “Non-physician clinicians can safely provide first trimester medicalabortion.” Reprod Health Matters 2009;17(33):61-9.
Breitbart V. “Counseling for medical abortion.” Am J Obstet Gynecol 2000;183(2 Suppl):S26-33.
Integration of medication abortion into medical practices Afable-Munsuz A, Gould H, Stewart F, Phillips KA, Van Bebber SL, Moore C. “Provider practice models forand costs of delivering medication abortion - evidence from 11 US abortion care settings.” Contraception2007;75(1):45-51.
Joffe C, Weitz TA. “Normalizing the exceptional: incorporating the "abortion pill" into mainstreammedicine.” Social Science & Medicine 2003;56(June):2353-2366.
Kawonga M, Blanchard K, Cooper D, Cullingworth L, Dickson K, Harrison T, et al. “Integrating medicalabortion into safe abortion services: experience from three pilot sites in South Africa.” J Fam PlannReprod Health Care 2008;34(3):159-64.
Leeman L, Asaria S, Espey E, Ogburn J, Gopman S, Barnett S. “Can mifepristone medication abortion besuccessfully integrated into medical practices that do not offer surgical abortion?” Contraception2007;76(2):96-100.
Shochet T, Trussell J. “Determinants of demand: method selection and provider preference among USwomen seeking abortion services.” Contraception 2008;77(6):397-404.
World Health Organization. Frequently Asked Clinical Questions about Medical Abortion. Conclusions ofan International Consensus Conference on Medical Abortion in Early First Trimester. Bellagio, Italy;2006.
Creinin MD. “Randomized comparison of efficacy, acceptability and cost of medical versus surgicalabortion.” Contraception 2000;62(3):117-24.
Lohr PA, Hayes JL, Gemzell-Danielsson K. “Surgical versus medical methods for second trimesterinduced abortion.” Cochrane Database Syst Rev 2008(1):CD006714.
Say L, Kulier R, Gulmezoglu M, Campana A. “Medical versus surgical methods for first trimestertermination of pregnancy.” Cochrane Database Syst Rev 2005(1):CD003037.
Wiegerinck MM, Jones HE, O'Connell K, Lichtenberg ES, Paul M, Westhoff CL. “Medical abortionpractices: a survey of National Abortion Federation members in the United States.” Contraception2008;78(6):486-91.
Creinin MD, Shore E, Balasubramanian S, Harwood B. “The true cost differential between mifepristoneand misoprostol and misoprostol-alone regimens for medical abortion.” Contraception2005;71(1):26-30.
Hu D, Grossman D, Levin C, Blanchard K, Goldie SJ. “Cost-effectiveness analysis of alternative first-trimester pregnancy termination strategies in Mexico City.” BJOG 2009;116(6):768-79.
Murthy A, Creinin MD. “Pharmacoeconomics of medical abortion: a review of cost in the United States,Europe and Asia.” Expert Opin Pharmacother 2003;4(4):503-13.
Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. “Patient costs for medication abortion: results from a study of five clinical practices.” Women's Health Issues 2006;16(1):4-13.
Hausknecht R. “Mifepristone and misoprostol for early medical abortion: 18 months experience in theUnited States.” Contraception 2003;67(6):463-5.
Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. “Rates of serious infection after changes inregimens for medical abortion.” N Engl J Med 2009;361(2):145-51.
Kruse B, Poppema S, Creinin MD, Paul M. “Management of side effects and complications in medicalabortion.” Am J Obstet Gynecol 2000;183(2 Suppl):S65-75.
Shannon C, Brothers LP, Philip NM, Winikoff B. “Infection after medical abortion: a review of theliterature.” Contraception 2004;70(3):183-90.
Virk J, Zhang J, Olsen J. “Medical abortion and the risk of subsequent adverse pregnancy outcomes.” NEngl J Med 2007;357(7):648-53.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. “Factors affecting the outcome of early medicalabortion: a review of 4132 consecutive cases.” BJOG2002;109(11):1281-9.
Hedley A, Trussell J, Turner AN, Coyaji K, Ngoc NT, Winikoff B, et al. “Differences in efficacy, differencesin providers: results from a hazard analysis of medical abortion.” Contraception 2004;69(2):157-63.

Source: http://www.ansirh.org/_documents/library/ANSIRHreading.medical.abortion.pdf